|
|
Volumn 10, Issue 6, 2001, Pages 1011-1019
|
|
Conventional cytotoxic and novel therapeutic concepts in colorectal cancer
|
|
Author keywords
5 FU; Chemotherapy; Colorectal cancer; Cytotoxic; Targets; Trials
|
|
Indexed keywords
CAMPTOTHECIN DERIVATIVE;
CAPECITABINE;
CISPLATIN DERIVATIVE;
CYTOTOXIC AGENT;
DNA;
DNA TOPOISOMERASE;
EPIDERMAL GROWTH FACTOR RECEPTOR;
FLOXURIDINE PHOSPHATE;
FLUOROURACIL;
FLUOROURACIL DERIVATIVE;
FOLINIC ACID;
GEFITINIB;
IRINOTECAN;
LEVAMISOLE;
LOPERAMIDE;
METHOTREXATE;
MITOGEN ACTIVATED PROTEIN KINASE;
OXALIPLATIN;
PLATINUM DERIVATIVE;
PROTEIN FARNESYLTRANSFERASE INHIBITOR;
PROTEIN TYROSINE KINASE;
PROTEIN TYROSINE KINASE INHIBITOR;
PYRIMIDINE;
RALTITREXED;
RAS PROTEIN;
THYMIDYLATE SYNTHASE;
TIPIFARNIB;
TRASTUZUMAB;
UFT;
UNINDEXED DRUG;
ADVANCED CANCER;
APOPTOSIS;
BONE MARROW SUPPRESSION;
BREAST CANCER;
CANCER ADJUVANT THERAPY;
CANCER CHEMOTHERAPY;
CANCER COMBINATION CHEMOTHERAPY;
CANCER INVASION;
CANCER MORTALITY;
CANCER PALLIATIVE THERAPY;
CANCER RECURRENCE;
CANCER STAGING;
CANCER SURGERY;
CANCER SURVIVAL;
CAUSE OF DEATH;
CELL CYCLE S PHASE;
CLINICAL FEATURE;
CLINICAL TRIAL;
COLORECTAL CANCER;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DIARRHEA;
DNA CROSS LINKING;
DNA STRAND BREAKAGE;
DNA SYNTHESIS INHIBITION;
DRUG ABSORPTION;
DRUG BIOAVAILABILITY;
DRUG HALF LIFE;
DRUG POTENTIATION;
DRUG SPECIFICITY;
DRUG STRUCTURE;
DRUG TARGETING;
ENZYME INHIBITION;
ERYTHEMA;
HUMAN;
IN VITRO STUDY;
MALIGNANT TRANSFORMATION;
MEMBRANE BINDING;
META ANALYSIS;
METASTASIS;
METHODOLOGY;
MODULATION;
MOLECULAR DYNAMICS;
MUCOSA INFLAMMATION;
MULTICENTER STUDY;
NAUSEA AND VOMITING;
NEUTROPENIA;
PERIPHERAL NEUROPATHY;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
RANDOMIZED CONTROLLED TRIAL;
RASH;
REVIEW;
SIGNAL TRANSDUCTION;
SYMPTOM;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS;
COLORECTAL NEOPLASMS;
HUMANS;
|
|
EID: 0034994538
PISSN: 13543784
EISSN: None
Source Type: Journal
DOI: 10.1517/13543784.10.6.1011 Document Type: Review |
|
Times cited : (30)
|
|
References (41)
|
